GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Price-to-Free-Cash-Flow

Oxford BioMedica (LSE:OXB) Price-to-Free-Cash-Flow : N/A (As of Jun. 10, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Price-to-Free-Cash-Flow?

As of today (2024-06-10), Oxford BioMedica's share price is £3.265. Oxford BioMedica's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.40. Hence, Oxford BioMedica's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Oxford BioMedica's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Oxford BioMedica's highest Price-to-Free-Cash-Flow Ratio was 627.38. The lowest was 15.78. And the median was 170.51.

LSE:OXB's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.56
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Oxford BioMedica's Free Cash Flow per Share for the six months ended in Dec. 2023 was £-0.29. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £-0.40.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -45.80% per year.

During the past 13 years, Oxford BioMedica's highest 3-Year average Free Cash Flow per Share Growth Rate was 70.10% per year. The lowest was -299.10% per year. And the median was 0.40% per year.


Oxford BioMedica Price-to-Free-Cash-Flow Historical Data

The historical data trend for Oxford BioMedica's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Price-to-Free-Cash-Flow Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 64.06 - -

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.06 - - - -

Competitive Comparison of Oxford BioMedica's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Oxford BioMedica's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Price-to-Free-Cash-Flow falls into.



Oxford BioMedica Price-to-Free-Cash-Flow Calculation

Oxford BioMedica's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.265/-0.397
=N/A

Oxford BioMedica's Share Price of today is £3.265.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.40.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Oxford BioMedica  (LSE:OXB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Oxford BioMedica Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (LSE:OXB) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines